 |
PDBsum entry 4zom
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Transcription
|
PDB id
|
|
|
|
4zom
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Transcription
|
 |
|
Title:
|
 |
Rorgamma in complex with inverse agonist 4j.
|
|
Structure:
|
 |
Nuclear receptor ror-gamma. Chain: a, b, c, d. Fragment: ligand binding domain. Synonym: nuclear receptor rzr-gamma,nuclear receptor subfamily 1 group f member 3,rar-related orphan receptor c,retinoid-related orphan receptor-gamma. Engineered: yes
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Gene: rorc, nr1f3, rorg, rzrg. Expressed in: escherichia coli. Expression_system_taxid: 469008.
|
|
Resolution:
|
 |
|
2.27Å
|
R-factor:
|
0.202
|
R-free:
|
0.240
|
|
|
Authors:
|
 |
D.J.Marcotte
|
|
Key ref:
|
 |
T.Wang
et al.
(2015).
Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Bioorg Med Chem Lett,
25,
2985-2990.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
06-May-15
|
Release date:
|
17-Jun-15
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P51449
(RORG_HUMAN) -
Nuclear receptor ROR-gamma from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
518 a.a.
223 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
Key: |
 |
PfamA domain |
 |
 |
 |
Secondary structure |
 |
 |
CATH domain |
 |
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Bioorg Med Chem Lett
25:2985-2990
(2015)
|
|
PubMed id:
|
|
|
|
|
| |
|
Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
|
|
T.Wang,
D.Banerjee,
T.Bohnert,
J.Chao,
I.Enyedy,
J.Fontenot,
K.Guertin,
H.Jones,
E.Y.Lin,
D.Marcotte,
T.Talreja,
K.Van Vloten.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
The nuclear receptor RORγ plays a central role in controlling a
pro-inflammatory gene expression program in several lymphocyte lineages
including TH17 cells. RORγ-dependent inflammation has been implicated in the
pathogenesis of several major autoimmune diseases and thus RORγ is an
attractive target for therapeutic intervention in these diseases. Starting from
a lead biaryl compound 4a, replacement of the head phenyl moiety with a
substituted aminopyrazole group resulted in a series with improved physical
properties. Further SAR exploration led to analogues (e.g., 4j and 5m) as potent
RORγ inverse agonists.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
 |